[{"orgOrder":0,"company":"Genascence","sponsor":"Pacira BioSciences","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Series A Financing","leadProduct":"sc-rAAV2.5IL-1Ra","moa":"IL-1 receptor","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Genascence","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"Genascence \/ Pacira BioSciences","highestDevelopmentStatusID":"8","companyTruncated":"Genascence \/ Pacira BioSciences"},{"orgOrder":0,"company":"Genascence","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"sc-rAAV2.5IL-1Ra","moa":"IL-1 receptor","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Genascence","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"Genascence \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Genascence \/ Undisclosed"},{"orgOrder":0,"company":"Genascence","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"sc-rAAV2.5IL-1Ra","moa":"IL-1 receptor","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Genascence","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"Genascence \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Genascence \/ Undisclosed"},{"orgOrder":0,"company":"Genascence","sponsor":"California Institute for Regenerative Medicine (CIRM)","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"GNSC-001","moa":"Interleukin-1 receptor antagonist protein (IL1RN)","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"Genascence","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"Genascence \/ California Institute for Regenerative Medicine (CIRM)","highestDevelopmentStatusID":"6","companyTruncated":"Genascence \/ California Institute for Regenerative Medicine (CIRM)"},{"orgOrder":0,"company":"Genascence","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"GNSC-001","moa":"Interleukin-1 receptor antagonist protein (IL1RN)","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"Genascence","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"Genascence \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Genascence \/ Undisclosed"}]